Literature DB >> 25901385

Management of Patients with a Genetic Variant of Unknown Significance

Suzanne M Mahon1.   

Abstract

Accurate risk assessment of developing cancer often includes genetic testing for germline mutations, which has clinical and treatment implications for the patient and his or her family members. When a mutation is detected, aggressive measures for cancer prevention and detection are often implemented. Depending on the gene or genes tested, a variable percentage of patients will receive a test report stating that a variant of unknown significance (VUS) has been detected. This means that a change in the genetic sequence has occurred, but whether the change is associated with an increased risk of cancer or another disease is unclear or unknown. The results are confusing and noninformative. Oncology nurses will undoubtedly encounter patients with a VUS; consequently, they need to understand the controversies and ambiguities that surround these test results. Resources that may be offered by healthcare providers and aid in patient understanding of VUS results are available (see Figure 1).

Entities:  

Keywords:  genetic testing; variant classification; variants of unknown significance

Mesh:

Year:  2015        PMID: 25901385     DOI: 10.1188/15.ONF.316-318

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  2 in total

1.  Analysis of state laws on informed consent for clinical genetic testing in the era of genomic sequencing.

Authors:  Kayte Spector-Bagdady; Anya E R Prince; Joon-Ho Yu; Paul S Appelbaum
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-03-22       Impact factor: 3.908

2.  Utilizing ClinGen gene-disease validity and dosage sensitivity curations to inform variant classification.

Authors:  Courtney Thaxton; Molly E Good; Marina T DiStefano; Xi Luo; Erica F Andersen; Erik Thorland; Jonathan Berg; Christa Lese Martin; Heidi L Rehm; Erin R Riggs
Journal:  Hum Mutat       Date:  2021-11-15       Impact factor: 4.700

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.